Cybin (OTCMKTS:CYBN) Shares Down 2.6% - Should You Sell?

Key Points

• Cybin Inc. shares fell by 2.6% during trading, closing at $7.26, with trading volume down 27% compared to the average.
• The company's market cap stands at $171.26 million and it has a PE ratio of -38.21.
• Cybin is focused on developing psychedelic-based therapeutics, with multiple compounds in various stages of clinical trials targeting mental health disorders.

Cybin Inc. (OTCMKTS:CYBN - ) was down 2.6% during trading on Monday . The stock traded as low as $7.26 and last traded at $7.26. Approximately 228,100 shares traded hands during trading, a decline of 27% from the average daily volume of 313,547 shares. The stock had previously closed at $7.45.

Cybin Trading Down 2.6%

The firm has a fifty day moving average price of $7.96 and a 200 day moving average price of $7.70. The firm has a market cap of $171.26 million, a PE ratio of -38.21 and a beta of 0.68.

About Cybin

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.